The DOI matches its Crossref record; 209 of the 209 references it cites were found in a registry or an index.
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Open accessAbstract
Cancer immunotherapy, as a paradigm shift in cancer treatment, has recently received tremendous attention. The active cancer vaccination, immune checkpoint blockage (ICB) and chimeric antigen receptor (CAR) for T‐cell‐based adoptive cell transfer are among these developments that have achieved a significant increase in patient survival in clinical trials. Despite these advancements, emerging research at the interdisciplinary interface of cancer biology, immunology, bioengineering, and materials science is important to further enhance the therapeutic benefits and reduce side effects. Here, an overview of the latest studies on engineering biomaterials for the enhancement of anticancer immunity is given, including the perspectives of delivery of immunomodulatory therapeutics, engineering immune cells, and constructing immune‐modulating scaffolds. The opportunities and challenges in this field are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–209 of 209
Landmark approval for Dendreon's cancer vaccine
DeFrancesco, L. (2010) · Nature Biotechnology · doi:10.1038/nbt0610-531 · Cited by 44
Ding, Q., Chen, J., Wei, X., Sun, W., Mai, J., Yang, Y., & Xu, Y. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0849-7 · Cited by 38
Engineering tolerance using biomaterials to target and control antigen presenting cells.
Tostanoski, L. H., Gosselin, E. A., & Jewell, C. M. (2016) · PubMed · Cited by 36
Biomaterial adjuvant effect is attenuated by anti-inflammatory drug delivery or material selection
Norton, L. W., Park, J., & Babensee, J. E. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.05.032 · Cited by 35
Ali, O. A., Doherty, E. J., Mooney, D. J., & Emerich, D. F. (2011) · Biomatter · doi:10.4161/biom.1.1.16277 · Cited by 35
Gong, H., Xiang, J., Xu, L., Song, X., Dong, Z., Peng, R., & Liu, Z. (2015) · Nanoscale · doi:10.1039/c5nr06081h · Cited by 27
Local delivery of checkpoints antibodies
Wang, C., Ye, Y., & Gu, Z. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1223000 · Cited by 20
Self-citationDane, E. L., & Irvine, D. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3398 · Cited by 18
First-line immunotherapy in lung cancer — taking the first step
Liu, S. V., & Giaccone, G. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.148 · Cited by 5
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
Chen, Q., Wang, C., Zhang, X., Chen, G., Hu, Q., Li, H., Wang, J., Wen, D., Zhang, Y., Lu, Y., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0319-4 · Cited by 1,010
Self-citationFunctional and Biomimetic Materials for Engineering of the Three-Dimensional Cell Microenvironment
Huang, G., Li, F., Zhao, X., Ma, Y., Li, Y., Lin, M., Jin, G., Lu, T. J., Genin, G. M., & Xu, F. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00094 · Cited by 825
Yang, R., Xu, J., Xu, L., Sun, X., Chen, Q., Zhao, Y., Peng, R., & Liu, Z. (2018) · ACS Nano · doi:10.1021/acsnano.7b09041 · Cited by 698
Wang, C., Wang, J., Zhang, X., Yu, S., Wen, D., Hu, Q., Ye, Y., Bomba, H., Hu, X., Liu, Z., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3682 · Cited by 591
Self-citation
Metadata
- Authors
- Wang, C., Ye, Y., Hu, Q., Bellotti, A., & Gu, Z.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2017-05-26
- Volume
- 29
- Issue
- 29
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W2616983963
- Cited by
- 286
- References
- 209
- FWCI
- 14.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.